AMERISAFE Falls 10% Post-Print, Analysts Trim Targets

AMSF has shed nearly 10% over the past week to $30.24, a meaningful deterioration since Q2 results landed — and the analyst community responded quickly, with Truist Securities cutting its price target to $32 from $34 yesterday while maintaining a Hold rating.

That target trim is the clearest post-print signal from the Street. Truist has now lowered its target four times in the past year, from $54 down to $32 — a steady ratcheting down that tracks the stock's own slide. The bull case, anchored in 5% gross written premium growth and 7.1% voluntary premium acceleration, remains intact as a structural argument. But bears are gaining ground: book value per share is growing only marginally, reserve development risks linger, and forward EPS momentum ranks in just the 13th percentile of the universe over 90 days. The consensus mean target of $35 sits above the current price, but the direction of travel — every recent analyst move has been a cut — tells the more relevant story.

The lending market has barely registered the selloff. Availability remains extraordinarily loose at roughly 4,588% of short interest, meaning there are close to 50 shares available to lend for every one borrowed. Short interest itself is 4.2% of the free float, ticking up 1.3% in one session but still down from its recent peak. Cost to borrow has edged up about 21% on the week but remains negligible at 0.73%. The options market is similarly calm: the put/call ratio of 0.44 runs just 0.8 standard deviations above its 20-day mean — mildly more defensive than usual, but nowhere near the kind of hedging pressure that would signal genuine alarm. Positioning looks cautious rather than crowded, with no meaningful short squeeze dynamic in play.